ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
People are being asked to participate in this study who have metastatic pancreatic cancer
(cancer that has spread to other parts of the body).
The purpose of this study is to test the efficacy (effectiveness) of a new combination of
drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with
metastatic pancreatic cancer.
ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this
enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and
will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body.